Tuberculosis associated with biological therapeutic agents
First case in Uruguay
Keywords:
RHEUMATOID ARTHRITIS, BIOLOGICAL THERAPY, TUBERCULOSIS
Abstract
Biologic therapies with anti-tumor necrosis factor alpha (TNF-?) monoclonal antibodies were a revolution in the treatment of rheumatoid arthritis. The use of antibodies implies a high risk of developing pulmonary tuberculosis and thus a thorough assessment is necessary, both upon the initiation of treatment and during patient follow up, to rule out a latent infection or active tuberculosis. The study presents the first clinical case of pulmonary tuberculosis associated with biologic therapy described in Uruguay (adalimumab).
References
(1) Rodríguez De Marco J. Tratamiento de la tuberculosis. Montevideo: Comisión Honoraria de Lucha Antituberculosa y Enfermedades Prevalentes, 2012. Disponible en: http://www.chlaep.org.uy/descargas/publicaciones/tratamiento-de-la-tuberculosis.pdf. Consulta: 30 abril 2012.
(2) Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345(15):1098-104.
(3) Farga V, Caminero JA. Tuberculosis. 3ª ed. Santiago de Chile: Mediterráneo, 2011. Capítulo 3; p. 27-58.
(4) Farga V, Caminero JA. Tuberculosis. 3ª ed. Santiago de Chile: Mediterráneo, 2011. Capítulo 3; p. 109-38.
(5) Algood HM, Lin PL, Flynn JL. Tumor necrosis factor and chemokine interactions in the formation and maintenance of granulomas in tuberculosis. Clin Infect Dis 2005; 41(Suppl 3):S189-93.
(6) Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010; 69(3):522-8.
(7) Beglinger C, Dudler J, Mottet C, Nicod L, Seibold F, Villiger PM, et al. Screening for tuberculosis infection before initiation of anti- TNF-? therapy. Swiss Med Wkly 2007; 137(43-44):620-2.
(8) Carmona L, Gómez-Reino JJ, Rodríguez-Valverde V, Montero D, Pascual-Gómez E, Mola EM, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005; 52(6):1766-72.
(9) Blanco Pérez JJ, Aranda Torres A, Pego Reigosa JM, Núñez Delgado M, Temes Montes E, Guerra Vales JL. Tuberculosis pulmonar en relación con adalimumab: estudio de 3 casos. Arch Bronconeumol 2010; 46(4):203-5.
(2) Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345(15):1098-104.
(3) Farga V, Caminero JA. Tuberculosis. 3ª ed. Santiago de Chile: Mediterráneo, 2011. Capítulo 3; p. 27-58.
(4) Farga V, Caminero JA. Tuberculosis. 3ª ed. Santiago de Chile: Mediterráneo, 2011. Capítulo 3; p. 109-38.
(5) Algood HM, Lin PL, Flynn JL. Tumor necrosis factor and chemokine interactions in the formation and maintenance of granulomas in tuberculosis. Clin Infect Dis 2005; 41(Suppl 3):S189-93.
(6) Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010; 69(3):522-8.
(7) Beglinger C, Dudler J, Mottet C, Nicod L, Seibold F, Villiger PM, et al. Screening for tuberculosis infection before initiation of anti- TNF-? therapy. Swiss Med Wkly 2007; 137(43-44):620-2.
(8) Carmona L, Gómez-Reino JJ, Rodríguez-Valverde V, Montero D, Pascual-Gómez E, Mola EM, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005; 52(6):1766-72.
(9) Blanco Pérez JJ, Aranda Torres A, Pego Reigosa JM, Núñez Delgado M, Temes Montes E, Guerra Vales JL. Tuberculosis pulmonar en relación con adalimumab: estudio de 3 casos. Arch Bronconeumol 2010; 46(4):203-5.
Published
2012-09-30
How to Cite
1.
Gruss AI, Torres S, Salisbury JP, Quintana E, Curbelo P. Tuberculosis associated with biological therapeutic agents. Rev. Méd. Urug. [Internet]. 2012Sep.30 [cited 2024May18];28(3):205-8. Available from: http://www2.rmu.org.uy/ojsrmu311/index.php/rmu/article/view/341
Section
Clinical Cases
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
